Global Pulmonary Drug Delivery Systems Market Growth 2025-2031

Publication ID:

LPI07254969

Publication Date:

July 4, 2025

Pages:

138

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Medical Devices [2]

Pharma & Healthcare [3]

Description:

The global Pulmonary Drug Delivery Systems market size is predicted to grow from US$ 3356 million in 2025 to US$ 4334 million in 2031; it is expected to grow at a CAGR of 4.4% from 2025 to 2031.
Pulmonary drug delivery systems are used to the treatment of various respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD), delivering locally acting drugs directly to their site of action. Advantages of pulmonary drug delivery systems over oral drugs is the excellent capability of absorbing pharmaceuticals, due to the large absorptive surface area of lungs (approximately 70-140 m2 in adult humans having extremely thin absorptive mucosal membrane) and good blood supply.
The major players in global Pulmonary Drug Delivery Systems market include 3M, GSK, AstraZeneca, etc. The top 3 players occupy about 60% shares of the global market. Europe and North America are main markets, they occupy over 75% of the global market. Metered Dose Inhaler (MDI) is the main type, with a share over 60%. COPD is the main application, which holds a share over 50%.
The 鈥淧ulmonary Drug Delivery Systems Industry Forecast鈥� looks at past sales and reviews total world Pulmonary Drug Delivery Systems sales in 2024, providing a comprehensive analysis by region and market sector of projected Pulmonary Drug Delivery Systems sales for 2025 through 2031. With Pulmonary Drug Delivery Systems sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Pulmonary Drug Delivery Systems industry.
This Insight Report provides a comprehensive analysis of the global Pulmonary Drug Delivery Systems landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Pulmonary Drug Delivery Systems portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Pulmonary Drug Delivery Systems market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Pulmonary Drug Delivery Systems and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Pulmonary Drug Delivery Systems.
This report presents a comprehensive overview, market shares, and growth opportunities of Pulmonary Drug Delivery Systems market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Nebulizers
Dry Powder Inhaler (DPI)
Metered Dose Inhaler (MDI)
Segmentation by Application:
COPD
Asthma
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
3M
GSK
AstraZeneca
Cipla
Chiesi
Boehringer Ingelheim
Aptar
Novartis
Philips Respironics
Omron Healthcare
PARI
Skyepharma
CareFusion
Shanghai Huarui
Taian Character
Chia Tai Tianqing
Key Questions Addressed in this Report
What is the 10-year outlook for the global Pulmonary Drug Delivery Systems market?
What factors are driving Pulmonary Drug Delivery Systems market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Pulmonary Drug Delivery Systems market opportunities vary by end market size?
How does Pulmonary Drug Delivery Systems break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Pulmonary Drug Delivery Systems Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Pulmonary Drug Delivery Systems by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Pulmonary Drug Delivery Systems by Country/Region, 2020, 2024 & 2031
2.2 Pulmonary Drug Delivery Systems Segment by Type
2.2.1 Nebulizers
2.2.2 Dry Powder Inhaler (DPI)
2.2.3 Metered Dose Inhaler (MDI)
2.3 Pulmonary Drug Delivery Systems Sales by Type
2.3.1 Global Pulmonary Drug Delivery Systems Sales Market Share by Type (2020-2025)
2.3.2 Global Pulmonary Drug Delivery Systems Revenue and Market Share by Type (2020-2025)
2.3.3 Global Pulmonary Drug Delivery Systems Sale Price by Type (2020-2025)
2.4 Pulmonary Drug Delivery Systems Segment by Application
2.4.1 COPD
2.4.2 Asthma
2.4.3 Others
2.5 Pulmonary Drug Delivery Systems Sales by Application
2.5.1 Global Pulmonary Drug Delivery Systems Sale Market Share by Application (2020-2025)
2.5.2 Global Pulmonary Drug Delivery Systems Revenue and Market Share by Application (2020-2025)
2.5.3 Global Pulmonary Drug Delivery Systems Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Pulmonary Drug Delivery Systems Breakdown Data by Company
3.1.1 Global Pulmonary Drug Delivery Systems Annual Sales by Company (2020-2025)
3.1.2 Global Pulmonary Drug Delivery Systems Sales Market Share by Company (2020-2025)
3.2 Global Pulmonary Drug Delivery Systems Annual Revenue by Company (2020-2025)
3.2.1 Global Pulmonary Drug Delivery Systems Revenue by Company (2020-2025)
3.2.2 Global Pulmonary Drug Delivery Systems Revenue Market Share by Company (2020-2025)
3.3 Global Pulmonary Drug Delivery Systems Sale Price by Company
3.4 Key Manufacturers Pulmonary Drug Delivery Systems Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Pulmonary Drug Delivery Systems Product Location Distribution
3.4.2 Players Pulmonary Drug Delivery Systems Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Pulmonary Drug Delivery Systems by Geographic Region
4.1 World Historic Pulmonary Drug Delivery Systems Market Size by Geographic Region (2020-2025)
4.1.1 Global Pulmonary Drug Delivery Systems Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Pulmonary Drug Delivery Systems Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Pulmonary Drug Delivery Systems Market Size by Country/Region (2020-2025)
4.2.1 Global Pulmonary Drug Delivery Systems Annual Sales by Country/Region (2020-2025)
4.2.2 Global Pulmonary Drug Delivery Systems Annual Revenue by Country/Region (2020-2025)
4.3 Americas Pulmonary Drug Delivery Systems Sales Growth
4.4 APAC Pulmonary Drug Delivery Systems Sales Growth
4.5 Europe Pulmonary Drug Delivery Systems Sales Growth
4.6 Middle East & Africa Pulmonary Drug Delivery Systems Sales Growth
5 Americas
5.1 Americas Pulmonary Drug Delivery Systems Sales by Country
5.1.1 Americas Pulmonary Drug Delivery Systems Sales by Country (2020-2025)
5.1.2 Americas Pulmonary Drug Delivery Systems Revenue by Country (2020-2025)
5.2 Americas Pulmonary Drug Delivery Systems Sales by Type (2020-2025)
5.3 Americas Pulmonary Drug Delivery Systems Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Pulmonary Drug Delivery Systems Sales by Region
6.1.1 APAC Pulmonary Drug Delivery Systems Sales by Region (2020-2025)
6.1.2 APAC Pulmonary Drug Delivery Systems Revenue by Region (2020-2025)
6.2 APAC Pulmonary Drug Delivery Systems Sales by Type (2020-2025)
6.3 APAC Pulmonary Drug Delivery Systems Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Pulmonary Drug Delivery Systems by Country
7.1.1 Europe Pulmonary Drug Delivery Systems Sales by Country (2020-2025)
7.1.2 Europe Pulmonary Drug Delivery Systems Revenue by Country (2020-2025)
7.2 Europe Pulmonary Drug Delivery Systems Sales by Type (2020-2025)
7.3 Europe Pulmonary Drug Delivery Systems Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Pulmonary Drug Delivery Systems by Country
8.1.1 Middle East & Africa Pulmonary Drug Delivery Systems Sales by Country (2020-2025)
8.1.2 Middle East & Africa Pulmonary Drug Delivery Systems Revenue by Country (2020-2025)
8.2 Middle East & Africa Pulmonary Drug Delivery Systems Sales by Type (2020-2025)
8.3 Middle East & Africa Pulmonary Drug Delivery Systems Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Pulmonary Drug Delivery Systems
10.3 Manufacturing Process Analysis of Pulmonary Drug Delivery Systems
10.4 Industry Chain Structure of Pulmonary Drug Delivery Systems
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Pulmonary Drug Delivery Systems Distributors
11.3 Pulmonary Drug Delivery Systems Customer
12 World Forecast Review for Pulmonary Drug Delivery Systems by Geographic Region
12.1 Global Pulmonary Drug Delivery Systems Market Size Forecast by Region
12.1.1 Global Pulmonary Drug Delivery Systems Forecast by Region (2026-2031)
12.1.2 Global Pulmonary Drug Delivery Systems Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Pulmonary Drug Delivery Systems Forecast by Type (2026-2031)
12.7 Global Pulmonary Drug Delivery Systems Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 3M
13.1.1 3M Company Information
13.1.2 3M Pulmonary Drug Delivery Systems Product Portfolios and Specifications
13.1.3 3M Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 3M Main Business Overview
13.1.5 3M Latest Developments
13.2 GSK
13.2.1 GSK Company Information
13.2.2 GSK Pulmonary Drug Delivery Systems Product Portfolios and Specifications
13.2.3 GSK Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 GSK Main Business Overview
13.2.5 GSK Latest Developments
13.3 AstraZeneca
13.3.1 AstraZeneca Company Information
13.3.2 AstraZeneca Pulmonary Drug Delivery Systems Product Portfolios and Specifications
13.3.3 AstraZeneca Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 AstraZeneca Main Business Overview
13.3.5 AstraZeneca Latest Developments
13.4 Cipla
13.4.1 Cipla Company Information
13.4.2 Cipla Pulmonary Drug Delivery Systems Product Portfolios and Specifications
13.4.3 Cipla Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Cipla Main Business Overview
13.4.5 Cipla Latest Developments
13.5 Chiesi
13.5.1 Chiesi Company Information
13.5.2 Chiesi Pulmonary Drug Delivery Systems Product Portfolios and Specifications
13.5.3 Chiesi Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Chiesi Main Business Overview
13.5.5 Chiesi Latest Developments
13.6 Boehringer Ingelheim
13.6.1 Boehringer Ingelheim Company Information
13.6.2 Boehringer Ingelheim Pulmonary Drug Delivery Systems Product Portfolios and Specifications
13.6.3 Boehringer Ingelheim Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Boehringer Ingelheim Main Business Overview
13.6.5 Boehringer Ingelheim Latest Developments
13.7 Aptar
13.7.1 Aptar Company Information
13.7.2 Aptar Pulmonary Drug Delivery Systems Product Portfolios and Specifications
13.7.3 Aptar Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Aptar Main Business Overview
13.7.5 Aptar Latest Developments
13.8 Novartis
13.8.1 Novartis Company Information
13.8.2 Novartis Pulmonary Drug Delivery Systems Product Portfolios and Specifications
13.8.3 Novartis Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Novartis Main Business Overview
13.8.5 Novartis Latest Developments
13.9 Philips Respironics
13.9.1 Philips Respironics Company Information
13.9.2 Philips Respironics Pulmonary Drug Delivery Systems Product Portfolios and Specifications
13.9.3 Philips Respironics Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Philips Respironics Main Business Overview
13.9.5 Philips Respironics Latest Developments
13.10 Omron Healthcare
13.10.1 Omron Healthcare Company Information
13.10.2 Omron Healthcare Pulmonary Drug Delivery Systems Product Portfolios and Specifications
13.10.3 Omron Healthcare Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Omron Healthcare Main Business Overview
13.10.5 Omron Healthcare Latest Developments
13.11 PARI
13.11.1 PARI Company Information
13.11.2 PARI Pulmonary Drug Delivery Systems Product Portfolios and Specifications
13.11.3 PARI Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 PARI Main Business Overview
13.11.5 PARI Latest Developments
13.12 Skyepharma
13.12.1 Skyepharma Company Information
13.12.2 Skyepharma Pulmonary Drug Delivery Systems Product Portfolios and Specifications
13.12.3 Skyepharma Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Skyepharma Main Business Overview
13.12.5 Skyepharma Latest Developments
13.13 CareFusion
13.13.1 CareFusion Company Information
13.13.2 CareFusion Pulmonary Drug Delivery Systems Product Portfolios and Specifications
13.13.3 CareFusion Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 CareFusion Main Business Overview
13.13.5 CareFusion Latest Developments
13.14 Shanghai Huarui
13.14.1 Shanghai Huarui Company Information
13.14.2 Shanghai Huarui Pulmonary Drug Delivery Systems Product Portfolios and Specifications
13.14.3 Shanghai Huarui Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Shanghai Huarui Main Business Overview
13.14.5 Shanghai Huarui Latest Developments
13.15 Taian Character
13.15.1 Taian Character Company Information
13.15.2 Taian Character Pulmonary Drug Delivery Systems Product Portfolios and Specifications
13.15.3 Taian Character Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 Taian Character Main Business Overview
13.15.5 Taian Character Latest Developments
13.16 Chia Tai Tianqing
13.16.1 Chia Tai Tianqing Company Information
13.16.2 Chia Tai Tianqing Pulmonary Drug Delivery Systems Product Portfolios and Specifications
13.16.3 Chia Tai Tianqing Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2020-2025)
13.16.4 Chia Tai Tianqing Main Business Overview
13.16.5 Chia Tai Tianqing Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂